Introduction
============

Hematopoietic stem cell transplantation (SCT) is a breakthrough curative treatment for refractory diseases, including hematopoietic malignances and autoimmune diseases, with roughly 50,000 procedures being performed annually worldwide ([@B1]). However, SCT therapy requires the administration of otherwise lethal doses of cytotoxic chemotherapy and immunosuppressors. Therefore, the management of serious adverse reactions and complications caused by these treatments is vital for success ([@B1]-[@B4]).

Among the complications associated with SCT, acute kidney injury (AKI) occurs frequently and is the most crucial to address, as it influences the prognosis of post-allogeneic SCT patients ([@B5]-[@B8]). Some survivors of AKI develop nephrotic syndrome within several years after allogeneic SCT ([@B8]-[@B10]), and some develop a gradual loss in the glomerular function, ultimately resulting in chronic kidney disease (CKD) ([@B11]-[@B16]). These kidney diseases place a heavy burden on SCT patients, both medically and economically ([@B16]). Therefore, hematologists evaluating SCT should be fully aware of the development of these kidney diseases after SCT. Furthermore, SCT requires cooperation by onco-nephrologists, who are experienced in the treatment of hematological malignancies and SCT procedures as well as facilitating the best treatment for renal disease in SCT recipients ([@B17], [@B18]).

This review describes the common course of kidney disease development following allogeneic SCT and provides information for healthcare professionals on the need for interventions by onco-nephrologists in the practice of SCT. The content of this review article was approved by the institutional committee on research ethics \[approval number: 29-furyo-rin (B)-2\].

Increasing Number of SCT Procedures and the Survival Rate of SCT Patients
=========================================================================

After SCT was initiated in the late 1950s in the US, treatment techniques markedly progressed, and therapeutic drugs were developed, which greatly improved the treatment outcomes. According to the Statistical Data of the Japanese Data Center for Hematopoietic Cell Transplantation (JDCHCT), the number of SCT applications is increasing in Japan every year ([@B19]). SCT was initiated in a few facilities in the 1970s in Japan, with fewer than 500 being performed annually; however, approximately 5,000 patients (allogeneic transplantation: 3,500 and autologous transplantation: 1,500) underwent SCT in 2015, reflecting a 10-fold increase ([Fig. 1](#g001){ref-type="fig"}).

![Trends in the annual number of allogeneic and autologous stem cell transplantation recipients for 25 years (1991 to 2015) in Japan. SCT was initiated in a few facilities in the 1970s in Japan, and approximately 1,000 were performed annually as of 1991; however, approximately 5,000 patients (allogeneic transplantation: 3,500 and autologous transplantation: 1,500) underwent SCT in 2015. Allo: allogeneic stem cell transplantation, Auto: autologous stem cell transplantation. This figure is cited courtesy of the Japanese Data Center for Hematopoietic Cell Transplantation (JDCHCT).](1349-7235-57-1503-g001){#g001}

SCT is divided into two types based on the preconditioning intensity-myeloablative and non-myeloablative (or reduced-intensity) SCT and is also divided into two types based on the donor of the hematopoietic stem cells used-the patient\'s own cells collected beforehand (autologous) and cells donated by a relative or others through a bone marrow bank (allogeneic). SCT is also classified into three types based on the hematopoietic stem cell source: bone marrow (BM), peripheral blood (PB), and cord blood (CB). Accordingly, a general description of SCT is myeloablative allogeneic PB stem cell transplantation ([@B3], [@B7], [@B12]). SCT is a breakthrough curative treatment mainly for hematological malignant cancers that has markedly improved the prognosis and quality of life of patients. However, SCT is also a highly toxic biological treatment that involves chemotherapy at a high dose, which is considered lethal, and total-body radiotherapy where necessary. Thus, patients are at risk of developing the serious adverse reactions and complications associated with these procedures.

The survival rate of patients markedly decreases to approximately 50% within 6 months after transplantation, regardless of the transplantation modality, and then slowly declines, plateauing at nearly 40% approximately 5 years after SCT, as shown in [Fig. 2](#g002){ref-type="fig"}. Accordingly, the avoidance and management of factors associated with mortality are pivotal for improving the survival rates. In allogeneic but not autologous SCT, nephrologists have noted that the development of AKI early after SCT was closely associated with an increased mortality rate in the early phase ([@B7], [@B8], [@B20], [@B21]). Thus, hematologists committed to SCT need to obtain a clearer understanding of current concepts and diagnostic criteria for AKI, monitor changes in laboratory data related to kidney disease, and consult a nephrologist as soon as AKI is suspected.

![Survival curves after stem cell transplantation for 25 years, stratified by donor types and stem cell sources. The probability of surviving markedly decreases to approximately 50% within 6 months of transplantation, regardless of the transplantation modality, and then slowly declines, plateauing at nearly 40% after approximately 5 years. Rel-BM: related-bone marrow, Auto: autologous transplantation, UR-BM: unrelated-bone marrow, UR-CB: unrelated-cord blood, and Rel-PB: related-peripheral blood. This figure is cited courtesy of the Japanese Data Center for Hematopoietic Cell Transplantation (JDCHCT).](1349-7235-57-1503-g002){#g002}

Time Course of Kidney Disease Development following Allogeneic SCT
==================================================================

Allogeneic SCT patients frequently develop kidney disease in three stages following allogeneic SCT. [Fig. 3](#g003){ref-type="fig"} shows the time course of kidney disease development. AKI develops at a frequency of approximately 70% within 100 days after allogeneic transplantation and is an emergent condition that directly influences the prognosis of many transplant patients. Severe AKI develops in the period of bone marrow failure prior to the engraftment of transplanted stem cells within 30 days of the implementation of SCT in about 20% of SCT recipients ([@B20]). Post-SCT AKI is more challenging to treat than normal AKI because patients are in a severely immunodeficient state and manifest complications of hemorrhagic tendencies, infections, and acute graft-versus-host disease (GVHD) in this period. Nearly 1% of patients who survive without AKI develop nephrotic syndrome, which is assumed to be associated with chronic GVHD, within several years of allogeneic SCT ([@B10]-[@B12], [@B22]). Some patients who survive AKI and nephrotic syndrome develop CKD ([@B12]-[@B14], [@B20], [@B23]), a few of whom (approximately 4-5%) ultimately advance to end-stage renal disease (ESRD) requiring chronic blood purification therapy ([@B23], [@B24]). Subclinical or insidious kidney damage before and after SCT may be identified by microalbuminuria, proteinuria, and/or urinary tubular biomarkers. Further details on each kidney disease are described below.

![Time course of kidney disease development following allogeneic hematopoietic stem cell transplantation. Early acute kidney injury (AKI) develops before stem cell engraftment, while late AKI develops after stem cell engraftment. Nephrotic syndrome (NS) develops on average approximately 1 to 2 years after allogeneic stem cell transplantation (SCT) in less than 1% of SCT recipients. Furthermore, some long-term survivors develop chronic kidney failure (CKD), and some of these patients may advance to end-stage renal disease (ESRD). The incidence of microalbuminuria, albuminuria, or proteinuria is a sign of future declines in the renal function. Baseline elevations in urinary liver-type fatty acid-binding protein (uL-FABP) portend the incidence of AKI after SCT. CY: cyclophosphamide, TBI: total-body irradiation, MTX: methotrexate, CyA: cyclosporine, and TAC: tacrolimus](1349-7235-57-1503-g003){#g003}

AKI following allogeneic SCT
----------------------------

Since Zager et al. ([@B5]) defined post-SCT acute renal failure (ARF) in 1989, it has been conventionally classified into three grades based on elevations in the serum creatinine (Cr) concentration within 100 days after SCT. In the US, Schrier et al. ([@B25]) reported the frequency of post-SCT ARF and mortality of patients 6 months to 1 year after SCT according to SCT modalities, in which the incidence of ARF was 21% in patients who received myeloablative autologous transplantation, 40% in those who received non-myeloablative allogeneic transplantation, and 69% in those who received myeloablative allogeneic transplantation, with mortality rates of 7%, 34%, and 58%, respectively. Ando et al. ([@B7]) examined the incidence of AKI based on the new concept of AKI using the Cr criteria defined by risk, injury, failure, loss of kidney function and end-stage kidney disease (RIFLE) and AKIN. The incidence of AKI that developed within 100 days after SCT was investigated in 249 patients who underwent SCT between August 2004 and December 2007. The overall incidences of AKI were 2%, 40-48%, and 62-66% in patients treated with autologous, non-myeloablative allogeneic, and myeloablative allogeneic SCT, respectively, and the cumulative mortality rates of patients who developed AKI of either severity during the follow-up period of approximately 3 years were 11-20%, 48-50%, and 54%, respectively. Furthermore, the mortality rate increased as the severity of AKI increased, regardless of the transplantation modality.

AKI with a poor prognosis frequently develops prior to hematopoietic stem cell engraftment (approximately 7-30 days after transplantation). Shingai et al. ([@B20]) recently clarified the relationship between the incidence of "AKI before stem cell engraftment" (early AKI) and patient prognoses. According to the findings of their prospective study on the incidence of AKI and mortality rates in 106 patients who underwent allogeneic SCT, the incidence of early AKI was approximately 20%, and its cumulative survival rate was 50-60%, showing a very poor survival even at 100 days after transplantation. This mortality rate was markedly higher than that (9%) in patients who developed AKI after engraftment (late AKI).

The causes of post-SCT AKI are complex; drugs used for preconditioning and prophylaxis for GVHD, infections including sepsis, circulatory failure, sinusoidal obstruction syndrome, and GVHD are concurrently involved ([@B2], [@B3], [@B23]). Furthermore, previous autopsy reports on SCT recipients ([@B6], [@B26]) have revealed no prominent histological changes in autopsied kidneys in most patients who developed severe AKI following SCT. Therefore, the renal function impairments were suggested to be mainly caused by hemodynamic rather than structural disorders.

Beyond our understanding of the precise pathophysiology of AKI, it is crucial, from a clinical perspective, to identify those patients predisposed to develop AKI following SCT, as it may help improve the prognosis of transplant recipients. The measurement of sensitive urinary tubular biomarkers represents a promising approach, as structural and/or functional tubular damage may initially emerge when renal and/or systemic stress occurs in the body. When the level of urinary liver-type fatty acid-binding protein (uL-FABP), a new biomarker of tubular ischemia or its injury, already exceeds the normal standard at baseline prior to the conditioning procedure, the risk of developing AKI increases by approximately 2.8-fold ([@B27]). In addition, increases in the level of urinary neutrophil gelatinase associated lipocalin (uNGAL) may augment the risk of AKI, and changes in the uNGAL concentrations at day +9 from baseline may be useful for predicting AKI in SCT recipients ([@B28]).

Incidence of albuminuria, proteinuria, and nephrotic syndrome after allogeneic SCT
----------------------------------------------------------------------------------

Garcia et al. ([@B29]) reported 2 nephrotic syndrome cases in 1988, showing that chronic GVHD developed in the kidneys following allogeneic SCT. Momoki et al. ([@B22]) surveyed the data of 1,175 patients who underwent allogeneic SCT over a 27-year period between January 1986 and December 2013. Nephrotic syndrome, which is considered to be associated with previous SCT, developed in 9 patients (frequency: 0.77%). The male-to-female ratio was 7:2, the mean age at the onset was 47.7±16.4 years old, the mean urinary protein amount was 6.5 (range: 3.8-13.6) g/day, and the mean time until the diagnosis of nephrotic syndrome was 24.8 (range: 15-35) months after SCT. The histological type based on a kidney biopsy was membranous nephropathy in 8 cases (89%) and minimal change type in 1 case. The stainability of IgG subclasses was IgG4 (9 cases) = IgG1 (9 cases) \> IgG3 (4 cases) \> IgG2 (2 cases). In previous studies on post-SCT nephrotic syndrome, the histological type was membranous nephropathy in more than 60% of cases of post-SCT nephrotic syndrome, followed by the minimal change type in 20%, and the subclass staining pattern of membranous nephropathy cases was similar ([@B9], [@B10]) to that described above.

Momoki et al. ([@B22]) also reported the clinical significance of incident proteinuria less than the nephrotic range (3.5 g/day). Proteinuria was prospectively investigated in all 693 allogeneic SCT recipients over 10 years between August 2004 and July 2014 and was monitored for ≥1 year after the implementation of allogeneic SCT. Within 1 year of transplantation, 1+ or more severe novel proteinuria persisted for ≥3 months in 57 patients (8.2%). The kidney function subsequently progressed to CKD \[estimated glomerular filtration rate (eGFR) \<60\] during the follow-up period in 41 patients (72%), and 5 patients (8.8%) advanced to ESRD.

Morito et al. ([@B30]) quantitatively measured microalbuminuria immediately after allogeneic SCT in 31 patients. Microalbuminuria became positive \[albumin creatinine ratio (ACR) ≥30 mg/g creatinine\] within 1 month of SCT in 16 patients (52%), and the 1-year cumulative incidence of CKD was 62.5% in these patients (8.3% in microalbuminuria-negative cases). Accordingly, both studies suggested that the patients who develop proteinuria or albuminuria, even that in the subclinical range, are at an increased risk of future CKD.

CKD among allogeneic SCT survivors and the strong relationship between CKD and prior AKI
----------------------------------------------------------------------------------------

Kidney disease progresses to CKD in some SCT patients who survive AKI or nephrotic syndrome. Hingorani et al. ([@B2]) reported that the cumulative incidence of CKD varied between 7% and 48% and developed between 6 months and 10 years after SCT. Risk factors for CKD include prior AKI, acute and chronic GVHD, an older age at SCT, a decrease in the GFR at baseline, hypertension, the use of calcineurin inhibitors, and exposure to total-body irradiation (TBI). However, CKD may be caused by a combination of these risk factors, including chronic GVHD, followed by chronic and persistent systemic inflammation, the long-term use of calcineurin inhibitors \[contributing to thrombotic microangiopathy (TMA) in glomeruli\], and prior exposure to TBI, which is relevant to vascular endothelium and tubular epithelium injury ([@B31]).

Ando et al. ([@B23]) examined 158 patients who survived for ≥3 years after allogeneic SCT between 1987 and 2003. The prevalence of CKD and its related factors were investigated in these patients. The CKD stage was ≥3 in 17% \[27 cases (stage 3, 8; stage 4, 10; and stage 5, 9)\]. Regarding factors associated with CKD, the strongest relationship was noted with prior AKI (OR9.92). In addition, Shimoi et al. ([@B32]) prospectively examined the serum Cr concentrations in 77 patients who underwent allogeneic SCT and followed these patients for ≥10 years \[median observation period: 14.4 (range: 10.5-20.2) years\]. The 10-year cumulative incidence of CKD (eGFR \<60) was 34% (26 cases). A factor related to CKD was prior AKI in the transplantation period, and its influence increased as the AKIN stage of AKI became more severe (hazard ratios: stage 1, 3.27; stage 2, 6.98; stage 3, 14.8).

Other studies have reported that AKI is a risk factor for CKD and influences the prognosis of patients with successful SCT (long-term survivors) ([@B2], [@B23], [@B33]). A further increase in the incidence of post-SCT CKD is anticipated due to the aging of transplantation recipients. Indeed, the rate of SCT recipients ≥50 years of age was approximately 5% ten years ago but will exceed 30% with the expansion of non-myeloablative conditioning and the recent increase in the number of haploidentical SCT cases ([@B34]).

Regarding the treatment of post-SCT CKD, use of angiotensin-converting enzyme inhibitors (ACEIs) or angiotensin II receptor antagonists seem promising, as their protective effects on the progression of post-SCT CKD have been shown in humans as well as in experimental models ([@B35], [@B36]).

Need for interventions by onco-nephrologists in the practice of SCT
-------------------------------------------------------------------

Recent advances have been achieved in treatment techniques and the development of therapeutic drugs in SCT, and the annual number of SCT applications recently exceeded that of kidney transplantation in the US ([@B1], [@B34]). Although a further increase in the number of SCT applications is expected, several issues, including the prevalence of kidney disease, have yet to be resolved. In order to improve the prognosis of SCT recipients, cooperation among onco-nephrologists with experience in the treatment of hematological malignancies and SCT procedures as well as knowledge of the pathophysiology of kidney disease and the best treatments for kidney disease is necessary ([@B17], [@B37]). The management of pre- and post-SCT patients by onco-nephrologists includes the identification of patients at increased risk for AKI prior to SCT and early after SCT when only minor changes in the serum Cr and/or elevations in uL-FABP and uNGAL levels are present, the application of interventions such as adjustment of drug dosing to avoid nephrotoxicity, the treatment of tumor- or treatment-related fluid and electrolytes abnormalities, and the early intervention with renal replacement therapy. In addition, a routine evaluation for the presence of albuminuria and/or proteinuria after SCT is pivotal for predicting the future burden of kidney disease, such as nephrotic syndrome and CKD, in SCT recipients.

Conclusions
-----------

AKI develops at a high frequency following allogeneic SCT and is generally induced by complex factors that are difficult to identify, potentially making such cases more intractable or lethal than AKI alone. Some long-term survivors develop nephrotic syndrome and advance to CKD or ESRD, which is likely associated with prior AKI. Hematologists who are committed to SCT should be fully aware of the development of these kidney diseases after SCT. Periodic monitoring for proteinuria and albuminuria after SCT is fundamental for identifying individuals at high risk of kidney disease. Furthermore, the professional management of post-SCT patients by onco-nephrologists is recommended. Cooperation among onco-nephrologists is increasingly needed in order to improve the prognosis of SCT recipients.
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